Search results
Results from the WOW.Com Content Network
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [ 4 ] Use is often recommended together with vitamin D , calcium supplementation , and lifestyle changes.
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women. [ 3 ] [ 2 ] [ 4 ] [ 6 ] Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005.
Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral ...
This type of drug has a high affinity for hydroxyapatite [28] and stays in bone tissue for a long period of time, [29] with alendronate, it has a half-life of approximately ten years. [30] The risk of a patient having MRONJ after discontinuing this medication is unknown. [30]
Classically, for clinical indications of an approved drug, TI refers to the ratio of the dose of the drug that causes adverse effects at an incidence/severity not compatible with the targeted indication (e.g. toxic dose in 50% of subjects, TD 50) to the dose that leads to the desired pharmacological effect (e.g. efficacious dose in 50% of ...
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels).
A dose of Eli Lilly's diabetes drug Mounjaro has limited availability through February 2024, according to the U.S. Food and Drug Administration's website, due to an increase in demand.
This page was last edited on 4 July 2008, at 16:41 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply ...